{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T20:19:53Z","timestamp":1772223593439,"version":"3.50.1"},"reference-count":0,"publisher":"Mattioli1885","license":[{"start":{"date-parts":[[2015,4,30]],"date-time":"2015-04-30T00:00:00Z","timestamp":1430352000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Pract Concept"],"abstract":"<jats:p>Background:\u00a0Sweet\u2019s syndrome, also referred to as acute febrile neutrophilic dermatosis, can either occur as an idiopathic disorder or associated with another condition, including cancer, or induced by exposure to a drug. Proton pump inhibitors selectively inhibit gastric parietal cell H+-K+-adenosine triphosphatase and are most commonly used for the treatment of gastroesophageal reflux disease.\r\nPurpose:\u00a0Proton pump inhibitor-associated Sweet\u2019s syndrome is described in a woman with recurrent breast cancer.\r\nMethods:\u00a0PubMed was used to search the following terms, separately and in combination: acute febrile neutrophilic dermatosis, breast cancer, malignancy, paraneoplastic, proton pump inhibitor, and Sweet\u2019s syndrome. All papers were reviewed and relevant manuscripts, along with their reference citations, were evaluated.\r\nResults:\u00a0Proton pump inhibitors have previously been associated with cutaneous adverse reactions including maculopapular rash, subacute cutaneous lupus erythematosus and toxic epidermal necrolysis. However, drug-induced Sweet\u2019s syndrome has not been observed in patients receiving proton pump inhibitors. The reported woman developed Sweet\u2019s syndrome after initial exposure and subsequent repeat challenge to proton pump inhibitors; subsequent studies also observed recurrence of her breast cancer presenting as metastases to her stomach and bone.\r\nConclusions:\u00a0Drug-induced Sweet\u2019s syndrome has most commonly been associated with granulocyte colony stimulating factor in oncology patients. Malignancy-associated Sweet\u2019s syndrome has been observed in patients with solid tumors, including breast cancer. Confirmation of proton pump inhibitor-induced Sweet\u2019s syndrome, by repeat challenge with another medication in the same class of drug, was observed in a woman with breast cancer; although the subsequent discovery of recurrent breast cancer presenting as gastric mucosa and vertebral metastases also raises the possibility of concurrent paraneoplastic Sweet\u2019s syndrome, her Sweet\u2019s syndrome symptoms and lesions resolved without recurrence while her recurrent metastatic visceral malignancy persisted. In summary, medication-associated Sweet\u2019s syndrome can occur in oncology patients and proton pump inhibitors should be added to the list of medications associated with the potential to cause drug-induced Sweet\u2019s syndrome.<\/jats:p>","DOI":"10.5826\/dpc.0502a23","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T15:36:29Z","timestamp":1635780989000},"page":"113-119","source":"Crossref","is-referenced-by-count":6,"title":["Proton pump inhibitor-induced Sweet\u2019s syndrome: report of acute febrile neutrophilic dermatosis in a woman with recurrent breast cancer"],"prefix":"10.5826","author":[{"given":"Philip R.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"27750","published-online":{"date-parts":[[2015,4,30]]},"container-title":["Dermatology Practical &amp; Conceptual"],"original-title":[],"link":[{"URL":"http:\/\/www.dpcj.org\/index.php\/dpc\/article\/download\/dermatol-pract-concept-articleid-dp0502a23\/419","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.dpcj.org\/index.php\/dpc\/article\/download\/dermatol-pract-concept-articleid-dp0502a23\/419","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T08:45:34Z","timestamp":1637311534000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.dpcj.org\/index.php\/dpc\/article\/view\/dermatol-pract-concept-articleid-dp0502a23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,30]]},"references-count":0,"URL":"https:\/\/doi.org\/10.5826\/dpc.0502a23","relation":{},"ISSN":["2160-9381"],"issn-type":[{"value":"2160-9381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,30]]}}}